| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Wednesday’s Close |
|---|---|---|---|---|---|
| BPMC | Blueprint Medicines Corporation | $68.7 | $3.02B | Buy |
Why Array BioPharma, Deciphera Pharmaceuticals, and Blueprint Medicines Are Up by Double Digits Today
https://www.fool.com/investing/2019/01/07/why-array-biopharma-deciphera-pharmaceuticals-and.aspx?source=iedfolrf0000001
Jan 07, 2019 - Shares of all three cancer-focused companies shot higher after one of their peers got bought out for a sizable premium.
0
Blueprint Medicines' (BPMC) CEO Jeff Albers on Q3 2018 Results - Earnings Call Transcript
https://seekingalpha.com/article/4215890-blueprint-medicines-bpmc-ceo-jeff-albers-q3-2018-results-earnings-call-transcript?source=feed_sector_healthcare
Oct 30, 2018 -
0
Blueprint Medicines 2018 Q3 - Results - Earnings Call Slides
https://seekingalpha.com/article/4215758-blueprint-medicines-2018-q3-results-earnings-call-slides?source=feed_sector_healthcare
Oct 30, 2018 - The following slide deck was published by Blueprint Medicines in conjunction with their 2018 Q3 earnings call.
0
Loxo Oncology And Blueprint Medicines Wrap Up Round 2 In RET Showdown
https://seekingalpha.com/article/4213787-loxo-oncology-blueprint-medicines-wrap-round-2-ret-showdown?source=feed_sector_healthcare
Oct 24, 2018 - Loxo Oncology (LOXO) and Blueprint Medicines (BPMC) both recently published updated results for their small molecule kinase inhibitors targeting RET altered thyroid cancer. Both companies reported inc
0
Blueprint Medicines (BPMC) Q3 Earnings Preview: What to Look Out For
http://www.zacks.com/stock/news/330186/blueprint-medicines-bpmc-q3-earnings-preview-what-to-look-out-for?cid=CS-ZC-FT-330186
Oct 23, 2018 - Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
Loxo Oncology: Out Of The Frying Pan And Into The Fire (Part 2/2)
https://seekingalpha.com/article/4200203-loxo-oncology-frying-pan-fire-part-2-2?source=feed_sector_healthcare
Aug 17, 2018 -
0
Core Biotech Buys #17: Positive Commentary For Gene Therapy And Our First Swap
https://seekingalpha.com/article/4178491-core-biotech-buys-17-positive-commentary-gene-therapy-first-swap?source=feed_tag_etf_portfolio_strategy
May 31, 2018 - FDA Commissioner Scott Gottlieb´s remarks concerning the potential of gene therapy, bode well for stocks participating in that theme.A clinical hold for CRISPR Therapeutics caused some concern but I p
0
Evelo Biosciences IPO: Undervalued, And Almost 40% Of It Is Cash
https://seekingalpha.com/article/4176837-evelo-biosciences-ipo-undervalued-almost-40-percent-cash?source=feed_tag_ipo_analysis
May 24, 2018 - The company has $81.5 million in cash that will be shown in the balance sheet of the next quarterly report.Taking into account the new cash, the company is trading at 2.5x its cash per share.Peers are
0
Core Biotech Buys #16: Taking Advantage Of Weakness To Add To Conviction Ideas
https://seekingalpha.com/article/4176184-core-biotech-buys-16-taking-advantage-weakness-add-conviction-ideas?source=feed_all_articles
May 22, 2018 - Recent weakness in the biotech sector is an opportunity to add to conviction holdings.My ¨Week in Review¨ blog post appears to have the makings of a permanent feature due to positive feedback received
0
Institutional Top Ideas Series: Opaleye Management
https://seekingalpha.com/article/4174919-institutional-top-ideas-series-opaleye-management?source=feed_all_articles
May 17, 2018 - Opaleye Management is a smaller fund with exceptional performance of late.Their top two holdings are heavily weighted and they are capitalizing on the targeted oncology theme as well.I provide a brief
0
Page 1>
Related Companies
| Name | Exchange | Price | Mkt Cap | |
| ARRY | Array BioPharma Inc. | NASDAQ | $13.73 | $2.91B |
| ASND | Ascendis Pharma A/S | NASDAQ | $68.28 | $2.87B |
| HZNP | Horizon Pharma plc | NASDAQ | $19.22 | $3.2B |
| EBS | Emergent Biosolutions, Inc. | NYSE | $64.89 | $3.25B |
| HRTX | Heron Therapeutics, Inc. | NASDAQ | $33.8 | $2.63B |
BPMC - Nasdaq
http://www.nasdaq.com/symbol/bpmc
Quote information directly from the exchange
SEC filings
Comparison
Ownership
Insiders
Institutions
Revenue/EPS
Competitors
Guru
Report
Analysts
Pre-market
Quote
Consultant
After hours
Transcripts
BPMC - Google Finance
https://www.google.com/finance?q=BPMC
Industry related info and international coverage
Summary
News
BPMC - Bloomberg
http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=BPMC
Original news and commentary from Bloomberg
Charts
Financials with pensions
Snapshot
Earnings
Transactions
People
Options